Welcome to our dedicated page for Nathans Famous SEC filings (Ticker: NATH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Every Nathan’s Famous filing tells a story that goes far beyond hot dogs. The 10-K annual report breaks down royalty income from hundreds of franchised stands, the impact of beef price swings on margins, and the growth trajectory of its branded product program in grocery aisles worldwide. If you have ever searched for “Nathan’s Famous SEC filings explained simply,” you already know how dense those reports can be.
Stock Titan’s AI reads each document the moment it hits EDGAR. Our platform turns a 300-page Nathan’s Famous annual report 10-K simplified into clear takeaways, highlights “Nathan’s Famous quarterly earnings report 10-Q filing” trends, and flags every “Nathan’s Famous 8-K material events explained.” You’ll also receive Nathan’s Famous Form 4 insider transactions real-time alerts so you can monitor “Nathan’s Famous executive stock transactions Form 4” without refreshing the EDGAR feed.
Whether you’re benchmarking franchise royalty percentages, tracking segment revenues, or verifying “Nathan’s Famous proxy statement executive compensation,” our AI-powered summaries, red-line comparisons, and keyword search save hours. Quickly answer questions such as “What did the CEO buy in the latest Nathan’s Famous insider trading Form 4 transactions?” or dive into “Nathan’s Famous earnings report filing analysis” to spot quarter-over-quarter shifts. One page, all filings, continuously updated—understanding Nathan’s Famous SEC documents with AI has never been easier.
Intellia Therapeutics, Inc. (NTLA) – Form 4 insider filing
EVP & CFO Edward J. Dulac III executed an automatic, non-volitional sale of 7,462 common shares on 23 Jul 2025 at $14.02 per share. The disposition was a mandatory “sell-to-cover” to satisfy federal and state tax-withholding obligations triggered by the vesting of RSUs on 22 Jul 2025.
Post-transaction, Dulac directly owns 106,062 NTLA shares; no indirect holdings or derivative security changes were reported. No options were exercised or granted, and the filing does not disclose any additional share sales or purchases.
The event does not materially alter management’s economic exposure to the company and should be viewed as administrative rather than discretionary trading activity.